As Bristol (BMY) Stock Rose, Botty Investors LLC Has Decreased Its Stake

October 2, 2018 - By Dolores Ford

Bristol-Myers Squibb Company (NYSE:BMY) LogoInvestors sentiment decreased to 0.78 in 2018 Q2. Its down 0.05, from 0.83 in 2018Q1. It is negative, as 94 investors sold BMY shares while 550 reduced holdings. 108 funds opened positions while 396 raised stakes. 1.14 billion shares or 1.65% more from 1.12 billion shares in 2018Q1 were reported. Tekla Mngmt Ltd Liability Com has invested 1.37% in Bristol-Myers Squibb Company (NYSE:BMY). Bath Savings Trust holds 16,337 shares. Southeast Asset Advsr holds 0.1% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 6,212 shares. Atwood Palmer Incorporated owns 12,396 shares. Alabama-based Birmingham Capital Mngmt Al has invested 1.58% in Bristol-Myers Squibb Company (NYSE:BMY). Sivik Global Health Ltd Liability Company, a Connecticut-based fund reported 135,000 shares. Ww Asset Incorporated accumulated 0.29% or 107,011 shares. New Jersey-based Peapack Gladstone has invested 0.9% in Bristol-Myers Squibb Company (NYSE:BMY). 3,984 are owned by Paragon Limited Liability Co. Oregon-based Mengis Cap has invested 1.51% in Bristol-Myers Squibb Company (NYSE:BMY). Country Club Na has invested 0.16% in Bristol-Myers Squibb Company (NYSE:BMY). Orbimed Advsrs Limited Liability Company invested 1.57% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Peak6 Investments Limited Partnership reported 82,852 shares. Gamco Invsts Et Al reported 556,603 shares. Jefferies Group Inc Ltd holds 0% or 2,239 shares.

Since April 30, 2018, it had 1 insider purchase, and 0 sales for $249,948 activity.

Botty Investors Llc decreased its stake in Bristol (BMY) by 97.46% based on its latest 2018Q2 regulatory filing with the SEC. Botty Investors Llc sold 66,009 shares as the company’s stock rose 12.85% with the market. The institutional investor held 1,720 shares of the major pharmaceuticals company at the end of 2018Q2, valued at $95,000, down from 67,729 at the end of the previous reported quarter. Botty Investors Llc who had been investing in Bristol for a number of months, seems to be less bullish one the $101.84B market cap company. The stock increased 0.49% or $0.31 during the last trading session, reaching $62.4. About 1.89M shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 4.27% since October 2, 2017 and is downtrending. It has underperformed by 19.89% the S&P500.

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on October, 25. They expect $0.89 earnings per share, up 18.67 % or $0.14 from last year’s $0.75 per share. BMY’s profit will be $1.45B for 17.53 P/E if the $0.89 EPS becomes a reality. After $1.01 actual earnings per share reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts -11.88 % negative EPS growth.

More important recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: which released: “Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock” on September 03, 2018, also published article titled: “A Snapshot Of Bristol-Myers Squibb’s Business & Outlook”, published: “Bristol-Myers Squibb’s TYK2 inhibitor successful in mid-stage psoriasis study” on September 12, 2018. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) was released by: and their article: “Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Presents at Morgan Stanley 16th Annual Global …” with publication date: September 13, 2018.

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Among 10 analysts covering Bristol Myers (NYSE:BMY), 1 have Buy rating, 0 Sell and 9 Hold. Therefore 10% are positive. Bristol Myers had 12 analyst reports since April 13, 2018 according to SRatingsIntel. The stock has “Buy” rating by Guggenheim on Tuesday, April 17. Morgan Stanley downgraded Bristol-Myers Squibb Company (NYSE:BMY) on Tuesday, April 17 to “Equal-Weight” rating. The rating was downgraded by UBS to “Hold” on Monday, May 21. The firm earned “Underperform” rating on Wednesday, April 18 by BMO Capital Markets. Credit Suisse maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Friday, July 27. Credit Suisse has “Neutral” rating and $61 target. The rating was maintained by Cowen & Co on Friday, April 20 with “Hold”. Jefferies maintained it with “Hold” rating and $6600 target in Friday, April 13 report. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Market Perform” rating by BMO Capital Markets on Friday, April 27. The rating was upgraded by Atlantic Securities to “Neutral” on Wednesday, August 8. As per Tuesday, April 17, the company rating was maintained by Bank of America.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News